Resilience inks manufacturing pact with ARCH-backed cell therapy startup as it preps for the long haul
When you’re aiming to be the “Foxconn” or “Amazon Web Services” of biotech manufacturing, it’s all about doing things differently.
Some of those traits are on display in Resilience’s latest deal, a strategic collaboration to make Be Bio’s B cell therapies — or at least the initial rare disease programs.
The pact marks the latest deal for a fast moving biomanufacturing startup, which has relationships in place with Takeda, Moderna, bluebird and Harvard.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.